Exploring the Gut-Brain Connection: Are Probiotics the Next Frontier in Alzheimer’s Disease Treatment?
Alzheimer’s disease (AD) is the most common form of dementia, historically considered exclusively as a neurological condition treated primarily with cholinergic and glutamatergic inhibitors. Recent evidence highlights the significant influence of peripheral systems, particularly the gut-brain axis, on AD pathology. The gut microbiota plays a critical role in both physiological and psychological functions, and its interactions may impact the integrity of the blood-brain barrier, potentially contributing to neurodegenerative processes. Emerging therapeutic strategies targeting the gut microbiome, including both pharmacological and non-pharmacological approaches such as probiotics and prebiotics, offer promising avenues for intervention. This review synthesizes current literature and illustrative data to elucidate the connections among the gut-brain axis, neuroinflammation, and neuroprotection, and their implications for the pathogenesis and potential treatment of AD.
Authors
- Gabriel Casagrande Zabot
- Adrielly Vargas Lídio
- Gabriela Serafim Keller (ORCID: https://orcid.org/0000-0003-1425-1487)
- Fernanda Guarino De Felice
- Eduarda Behenck Medeiros
- Gabriela Piovesan Fenilli
- Josiane Budni
- Bruno Kluwe-Schiavon
- Gustavo de Bem Silveira
- Flávio Rigoberto Arriagata Carrion
- Consuelo Walls-Bass
- Tatiana Barichello
Institutions
- Universidade Federal do Rio de Janeiro (BR)
- Queen's University (CA)
- D’Or Institute for Research and Education (BR)
- Universidad Santo Tomás (CL)
- The University of Texas Health Science Center (US)
- Universidade do Extremo Sul Catarinense (BR)
Publication Details
- Journal
- Probiotics and Antimicrobial Proteins
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1007/s12602-026-10927-w
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.00